BridgeBio Oncology director granted 31,675 options

BridgeBio Oncology Therapeutics director and 10% owner Chen Bihua received a grant of stock options for 31,675 shares of common stock.

Rhea-AI Filing Summary

BridgeBio Oncology Therapeutics director and 10% owner Chen Bihua received a grant of stock options for 31,675 shares of common stock. The options have an exercise price of $7.73 per share and expire on June 15, 2036.

The options vest in full on the earlier of the first anniversary of the grant date or the next Annual Meeting of Stockholders that follows the grant date, provided Chen continues to serve the company through that vesting date. After this grant, Chen holds 31,675 derivative securities directly.

Insider Trade Summary

Grant/Award: 31,675 shares

Grant/Award 1 txn

Insider Chen Bihua

Role Director, 10% Owner

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	31,675	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 31,675 contracts (Direct)

Footnotes (1)

1. F1. The shares underlying the stock option vest in full upon the earlier of (i) the first anniversary of the date of grant or (ii) the date of the next Annual Meeting of Stockholders of the Issuer following the date of grant, subject to the Reporting Person's continued service to the Issuer through the applicable vesting date.

Key Figures

Options granted: 31,675 options Exercise price: $7.73 per share Underlying shares: 31,675 shares +2 more

5 metrics

Options granted 31,675 options Stock Option (Right to Buy) grant to Chen Bihua

Exercise price $7.73 per share Exercise price of granted stock options

Underlying shares 31,675 shares Common stock underlying the stock options

Expiration date June 15, 2036 Option expiration date

Post-grant derivative holdings 31,675 derivatives Total derivative securities held after this grant

Key Terms

Stock Option (Right to Buy), exercise price, Annual Meeting of Stockholders, vesting, +1 more

5 terms

Stock Option (Right to Buy) financial

"security_title: Stock Option (Right to Buy)"

exercise price financial

"conversion_or_exercise_price: 7.7300"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

Annual Meeting of Stockholders financial

"the date of the next Annual Meeting of Stockholders of the Issuer"

vesting financial

"The shares underlying the stock option vest in full upon the earlier of"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

ten percent owner regulatory

"is_ten_percent_owner: 1"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did BridgeBio Oncology Therapeutics (BBOT) report in this Form 4?

BridgeBio Oncology Therapeutics reported that director and 10% owner Chen Bihua received a grant of 31,675 stock options. These options relate to the company’s common stock and represent compensation rather than an open-market share purchase or sale.

How many BridgeBio Oncology (BBOT) options were granted to Chen Bihua?

The filing shows a grant of 31,675 stock options to director and 10% owner Chen Bihua. Each option is exercisable into one share of BridgeBio Oncology common stock, subject to vesting and an exercise price specified in the award.

What is the exercise price of Chen Bihua’s BBOT stock options?

The granted stock options have an exercise price of $7.73 per share. This means Chen must pay $7.73 for each share of common stock when exercising the options, once they are vested and before the stated expiration date.

When do Chen Bihua’s BridgeBio Oncology options vest?

The options vest in full on the earlier of the first anniversary of the grant date or the next Annual Meeting of Stockholders after the grant. Vesting requires Chen’s continued service with BridgeBio Oncology through the applicable vesting date.

When do the newly granted BBOT stock options expire?

The granted stock options expire on June 15, 2036. If they are not exercised by that expiration date, they lapse. The options can only be exercised after they vest and while Chen continues to satisfy any applicable service conditions.

Is this BBOT Form 4 a stock purchase or a compensation grant?

This Form 4 reflects a compensation-related grant of stock options, not an open-market stock purchase or sale. The options were awarded to director and 10% owner Chen Bihua at a preset exercise price and subject to vesting conditions.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/18/2026 - 04:55 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Chen Bihua

(Last) (First) (Middle)

C/O CORMORANT ASSET MANAGEMENT, LP

200 CLARENDON ST, 50TH FLOOR

(Street)

BOSTON MASSACHUSETTS 02116

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
BridgeBio Oncology Therapeutics, Inc. [ BBOT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/16/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$7.73	06/16/2026		A		31,675		(1)	06/15/2036	Common Stock	31,675	$0	31,675	D

Explanation of Responses:

1. The shares underlying the stock option vest in full upon the earlier of (i) the first anniversary of the date of grant or (ii) the date of the next Annual Meeting of Stockholders of the Issuer following the date of grant, subject to the Reporting Person's continued service to the Issuer through the applicable vesting date.

	/s/ Bihua Chen	06/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)